WorldHeart/Edwards Pump Up Novacor As Destination Therapy In Europe
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart and marketing partner Edwards Lifesciences will promote the Novacor left ventricular assist device (LVAD) as a destination therapy for heart failure patients in Europe following CE mark approval of a package of device enhancements, expected by the end of May